Etoposide-induced DNA cleavage in human leukemia cells

Abstract

The nuclear enzyme, topoisomerase II, is the major site of action for cancer chemotherapy agents such as etoposide, teniposide, and a variety of intercalating agents. These compounds cause the enzyme to cleave DNA, forming a DNA-protein complex that may be a key step leading to cell death. It is apparently unique as a chemotherapy target, since drug potency diminishes with decreasing enzyme activity. It was thus of interest to examine the topoisomerase content and drug-induced DNA cleavage in freshly obtained human leukemia cells and to compare the obtained data with the results of similar studies performed in well-characterized human leukemia cell lines. The human T-lymphoblast line, CCRF-CEM, was more than 100-fold more sensitive to the DNA-cleavage effect of etoposide than the cells of the 13 leukemic patients examined. One of the leukemia lines (HL-60) and a lymphoblastoid line (RPMI-7666) were somewhat less sensitive than cells of the CCRF-CEM cells, but were still 10-fold more sensitive than the patients studied. The relative insensitivity of the freshly obtained cells could not be accounted for by differences with respect to drug uptake but were associated with markedly reduced topoisomerase-II content as assayed by immunoblotting using a mouse polyclonal serum against topoisomerase II. Heterogeneity was observed in the sensitivities of patients' cells with respect to both drug-induced DNA cleavage and enzyme content. The observed differences between cultured cell lines and patients' cells may have been related to their proliferative status. Etoposide potency in normal resting lymphocytes resembles that observed in circulating leukemia cells. However, following mitogenesis with phytohemagglutinin and interleukin-2, proliferating lymphocytes become as sensitive to etoposide as cultured cell lines with regard to DNA cleavage. This effect was accompanied by an increase in topoisomerase-II content. Our data thus support the hypothesis that topoisomerase-II content may be an important determinant of cell sensitivity to certain classes of chemotherapy agents. Efforts to stimulate topoisomerase-II content may improve the therapeutic efficacy of these drugs.

Addition of Etoposide to Initial Therapy of Adult Acute Lymphoblastic Leukemia: A Combined Clinicaland Laboratory Study

“…However, these Pgp-mediated changes in drug accumulation appear to be too small to account for the marked decrease in drug-stabilized top0 11-DNA adducts reported by Edwards ef al. 42 These results prompted us to examine additional aspects of top0 11-mediated drug action as well. …”

Eliminating Encephalitogenic T Cells without Undermining Protective Immunity

“…Etoposide is a topoisomerase inhibitor (20, 21) that is used clinically to treat a variety of cancers and hemophagocytic lymphohistiocytosis (HLH) (22), a primary immune deficiency where aberrant T cell responses lead to immune mediated pathology. In parallel studies by our group (Johnson et.…”

Etoposide, an anticancer drug involved in therapy-related secondary leukemia: Enzymes at play

“…Once the inhibitor interacts with TOP2, the TOP2cc is trapped, leading to an accumulation of DSB. If the DSB cannot be repaired timely, the cell will initiate apoptosis and eventually die [ 33 , 34 ]. In contrast, if the DSB cell survives, it gives rise to the prospect of faulty DNA repair events, and the gene translocation could occur in the MLL gene, which is known for leukemogenesis.…”